The stock of TELA Bio Inc (TELA) has gone up by 0.38% for the week, with a -8.59% drop in the past month and a -6.67% drop in the past quarter. The volatility ratio for the week is 7.38%, and the volatility levels for the past 30 days are 6.78% for TELA. The simple moving average for the past 20 days is -3.50% for TELA’s stock, with a -28.16% simple moving average for the past 200 days.
Is It Worth Investing in TELA Bio Inc (NASDAQ: TELA) Right Now?
Company’s 36-month beta value is 1.00.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TELA is 30.77M, and currently, short sellers hold a 1.14% ratio of that floaft. The average trading volume of TELA on January 31, 2025 was 180.04K shares.
TELA) stock’s latest price update
TELA Bio Inc (NASDAQ: TELA) has experienced a decline in its stock price by -3.97 compared to its previous closing price of 2.77. However, the company has seen a gain of 0.38% in its stock price over the last five trading days. globenewswire.com reported 2025-01-24 that MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the “Grant Date”). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
Analysts’ Opinion of TELA
Many brokerage firms have already submitted their reports for TELA stocks, with Lake Street repeating the rating for TELA by listing it as a “Buy.” The predicted price for TELA in the upcoming period, according to Lake Street is $17 based on the research report published on May 31, 2022 of the previous year 2022.
TELA Trading at -6.65% from the 50-Day Moving Average
After a stumble in the market that brought TELA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -64.63% of loss for the given period.
Volatility was left at 6.78%, however, over the last 30 days, the volatility rate increased by 7.38%, as shares sank -8.28% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.50% lower at present.
During the last 5 trading sessions, TELA rose by +0.38%, which changed the moving average for the period of 200-days by -45.93% in comparison to the 20-day moving average, which settled at $2.76. In addition, TELA Bio Inc saw -11.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TELA starting from Cuca Roberto, who purchase 64,444 shares at the price of $2.25 back on Oct 24 ’24. After this action, Cuca Roberto now owns 155,388 shares of TELA Bio Inc, valued at $144,999 using the latest closing price.
Talmo Paul, the Chief Technology Officer of TELA Bio Inc, purchase 22,222 shares at $2.25 during a trade that took place back on Oct 24 ’24, which means that Talmo Paul is holding 91,082 shares at $50,000 based on the most recent closing price.
Stock Fundamentals for TELA
Current profitability levels for the company are sitting at:
- -0.66 for the present operating margin
- 0.68 for the gross margin
The net margin for TELA Bio Inc stands at -0.6. The total capital return value is set at -1.26. Equity return is now at value -342.03, with -59.18 for asset returns.
Based on TELA Bio Inc (TELA), the company’s capital structure generated 1.18 points at debt to capital in total, while cash flow to debt ratio is standing at -1.09. The debt to equity ratio resting at -6.62. The interest coverage ratio of the stock is -8.52.
Currently, EBITDA for the company is -40.63 million with net debt to EBITDA at -0.69. When we switch over and look at the enterprise to sales, we see a ratio of 1.88. The receivables turnover for the company is 6.12for trailing twelve months and the total asset turnover is 1.29. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.62.
Conclusion
In a nutshell, TELA Bio Inc (TELA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
